Initiator Pharma A/S publishes information memorandum in connection with the change of listing to Nasdaq First North Growth Markets

On Monday October 7, 2021 Nasdaq Stockholm AB approved Initiator Pharma A/S (“Initiator Pharma” or the “Company”) application for admission to trading of the Company’s shares on Nasdaq First North Growth Markets in Stockholm. Today, the Company publishes an information memorandum, in accordance with Nasdaq First North Growth Markets rules for application.

The memorandum is available as attached pdf file and on the Company’s website https://initiatorpharma.com/investors/. The memorandum is not a prospectus, has not been approved by the Danish Financial Supervisory Authority (Dk. Finanstilsynet) and does not contain any offering of shares or any other offering of financial instruments in the Company in Denmark, Sweden or in any other jurisdiction.

Redeye AB has been appointed as the Company’s Certified Adviser on Nasdaq First North. In connection with the list change, DLA Piper Denmark and DLA Piper Sweden has acted as the Company’s legal advisor.

For additional information about Initiator Pharma, please contact:

Claus Elsborg Olesen, CEO
Telephone: +45 6126 0035 E-mail: ceo@initiatorpharma.com

The information was submitted for publication, through the agency of the contact person set out above on 18 October 2021 at 08:30.

About Initiator Pharma

Initiator Pharma A/S is a Danish clinical stage life science company developing innovative drugs that target key unmet medical needs within the central and peripheral nervous system. Initiator Pharma’s pipeline consists of three clinical programs – the drug candidates IP2018 and IPED2015 for treatment of erectile dysfunction of psychogenic and organic origin, respectively, and the orphan drug candidate IPTN2021 developed for Trigeminal Neuralgia, a severe neuropathic pain condition. Initiator Pharma is listed on Spotlight Stockmarket (ticker: INIT).